CR20220068A - Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr - Google Patents
Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atrInfo
- Publication number
- CR20220068A CR20220068A CR20220068A CR20220068A CR20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A CR 20220068 A CR20220068 A CR 20220068A
- Authority
- CR
- Costa Rica
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- morpholinopyridine
- derivatives
- Prior art date
Links
- XHPVOSNOIWGRQQ-UHFFFAOYSA-N 4-pyridin-2-ylmorpholine Chemical class C1COCCN1C1=CC=CC=N1 XHPVOSNOIWGRQQ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220068A true CR20220068A (es) | 2022-06-30 |
Family
ID=74192632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220068A CR20220068A (es) | 2019-07-22 | 2020-07-22 | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (enExample) |
| EP (1) | EP4003993A4 (enExample) |
| JP (2) | JP7617076B2 (enExample) |
| KR (1) | KR20220035925A (enExample) |
| CN (1) | CN114174292B (enExample) |
| AU (1) | AU2020317381A1 (enExample) |
| BR (1) | BR112022000431A2 (enExample) |
| CA (1) | CA3148278A1 (enExample) |
| CO (1) | CO2022001853A2 (enExample) |
| CR (1) | CR20220068A (enExample) |
| EC (1) | ECSP22012347A (enExample) |
| IL (1) | IL289763A (enExample) |
| MX (1) | MX2022000854A (enExample) |
| PH (1) | PH12022550156A1 (enExample) |
| UA (1) | UA129807C2 (enExample) |
| WO (1) | WO2021012049A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| EP4072551A4 (en) * | 2019-12-11 | 2023-11-15 | Repare Therapeutics Inc. | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS |
| JP2024516821A (ja) * | 2021-04-28 | 2024-04-17 | リペア セラピューティクス インコーポレイテッド | 両アレル機能喪失型変異または遺伝子過剰発現変異を有するがんを治療する方法 |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
| TW202321256A (zh) * | 2021-07-27 | 2023-06-01 | 大陸商上海輝啟生物醫藥科技有限公司 | ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121969626A (zh) * | 2023-09-27 | 2026-05-01 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030141B1 (ru) * | 2009-12-31 | 2018-06-29 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| ES2865330T3 (es) * | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| CA3011189C (en) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko not_active Ceased
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en not_active Abandoned
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021012049A1 (en) | 2021-01-28 |
| CN114174292B (zh) | 2024-06-18 |
| EP4003993A1 (en) | 2022-06-01 |
| JP7758895B2 (ja) | 2025-10-22 |
| BR112022000431A2 (pt) | 2022-03-03 |
| CO2022001853A2 (es) | 2022-03-29 |
| UA129807C2 (uk) | 2025-08-06 |
| JP2022541825A (ja) | 2022-09-27 |
| CA3148278A1 (en) | 2021-01-28 |
| IL289763A (en) | 2022-03-01 |
| PH12022550156A1 (en) | 2023-05-08 |
| KR20220035925A (ko) | 2022-03-22 |
| WO2021012049A8 (en) | 2021-04-15 |
| MX2022000854A (es) | 2022-02-10 |
| US20220185809A1 (en) | 2022-06-16 |
| AU2020317381A1 (en) | 2022-02-10 |
| EP4003993A4 (en) | 2023-01-18 |
| ECSP22012347A (es) | 2022-03-31 |
| CN114174292A (zh) | 2022-03-11 |
| JP2025061048A (ja) | 2025-04-10 |
| JP7617076B2 (ja) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022001853A2 (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| AR130689A1 (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| UY26968A1 (es) | Agentes terapéuticos | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2012001699A1 (es) | Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
| MX389581B (es) | Compuestos que contienen nitrogeno sustituido. | |
| PA8589601A1 (es) | Derivados de indazol como antagonistas del crf | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. |